Therapy Areas: AIDS & HIV
SenzaGen enters into first global licensing agreement with Eurofins BPT Munich
19 February 2018 -

Genetic testing company SenzaGen (Nasdaq First North:SENZA) announced on Friday that it intends to market the GARD test to its clients via a global licensing agreement with the leading contract research organisation Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich).

Eurofins BPT Munich is the largest network of harmonized bio/pharmaceutical GMP/GLP product testing laboratories worldwide with 30 facilities all over the world, providing comprehensive laboratory services for the world's major pharmaceutical, biopharmaceutical and medical device companies.

SenzaGen's GARD is a genome-based test, with higher accuracy than other available test methods that gives the customers important safety information whether chemical substances are at risk of causing allergies in humans. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability.

Additionally, SenzaGen's GARDskin test is in the process of obtaining regulatory approval and inclusion in international test guidelines. It has the potential in the cosmetics and pharmaceutical industries for reliable, animal-free testing methods to assess the allergy-inducing properties of chemical substances.

In conjunction, Eurofins BioPharma Product Testing's Munich subsidiary was part of the successful ring trial in the validation of GARDskin.

Pursuant to the agreement, Eurofins BPT Munich will immediately include GARDskin and the add on test GARDpotency as a leading diagnostic tool in its chemical safety testing services to clients in the cosmetic, chemical and pharmaceutical industries worldwide.

Login
Username:

Password: